Supernus Pharmaceuticals SUPN Business Segments — Total external development program expenses

Similar metrics at other companies

TVTXReportable Segment — External research and development

$27.73M+24.0%

IBRXReportable Segment — External research and development expense (including amounts with related parties)

$20.08M+264%

INCYReportable Segment — Research and development - external

$243.13M+25.7%

MIRMReportable Segment — Research and development expenses (excluding stock-based compensation)

$73.72M+106%

RCUSReportable segment — Early-stage development and preclinical programs

$18M-57.1%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

Questions, answered.

What is Supernus Pharmaceuticals's business segments — total external development program expenses?

Supernus Pharmaceuticals (SUPN) reported business segments — total external development program expenses of $27.68M in Q1 2026.

How has Supernus Pharmaceuticals's business segments — total external development program expenses changed year-over-year?

Supernus Pharmaceuticals's business segments — total external development program expenses increased by 68.4% year-over-year, from $16.43M to $27.68M.

What is the long-term trend for Supernus Pharmaceuticals's business segments — total external development program expenses?

Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — total external development program expenses has grown at a 13.1% compound annual growth rate (CAGR), from $42.99M to $62.17M.

What does business segments — total external development program expenses mean?

Represents payments made to third-party organizations, such as contract research organizations, for clinical trials and drug development activities. This metric highlights the company's reliance on external partners to advance its pipeline of neurological treatments.